S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM)

$28.25
-1.31 (-4.43%)
(As of 12/5/2023 ET)
Compare
Today's Range
$28.10
$29.36
50-Day Range
$17.69
$30.76
52-Week Range
$16.95
$51.60
Volume
714,954 shs
Average Volume
989,395 shs
Market Capitalization
$2.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.80

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
72.7% Upside
$48.80 Price Target
Short Interest
Bearish
16.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Beam Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$73,343 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.85) to ($4.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

473rd out of 948 stocks

Biological Products, Except Diagnostic Industry

71st out of 147 stocks


BEAM stock logo

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

BEAM Stock News Headlines

CRISPR Gene Editing: Beam Therapeutics
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Is Beam Therapeutics Stock a Buy Now?
What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Lilly buys out Beam in heart drug alliance with Verve
Beam sells opt-in rights to Eli Lilly for up to $600M
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
439
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$48.80
High Stock Price Target
$105.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+71.3%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$-289,090,000.00
Net Margins
-384.62%
Pretax Margin
-383.39%

Debt

Sales & Book Value

Annual Sales
$60.92 million
Book Value
$10.41 per share

Miscellaneous

Free Float
77,918,000
Market Cap
$2.32 billion
Optionable
Not Optionable
Beta
1.69

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price target for 2024?

11 brokerages have issued twelve-month price targets for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's share price to reach $48.80 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 at the beginning of the year. Since then, BEAM shares have decreased by 27.8% and is now trading at $28.25.
View the best growth stocks for 2023 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.33) by $0.11. The business earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. The company's revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.56) EPS.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
This page (NASDAQ:BEAM) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -